Advertisement

Table of Contents

December 14, 2017; 130 (24)

INSIDE BLOOD COMMENTARIES

PLENARY PAPER

REVIEW ARTICLE

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

  • Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
    Hervé Avet-Loiseau, Nizar J. Bahlis, Wee-Joo Chng, Tamas Masszi, Luisa Viterbo, Ludek Pour, Peter Ganly, Antonio Palumbo, Michele Cavo, Christian Langer, Andrzej Pluta, Arnon Nagler, Shaji Kumar, Dina Ben-Yehuda, S. Vincent Rajkumar, Jesus San-Miguel, Deborah Berg, Jianchang Lin, Helgi van de Velde, Dixie-Lee Esseltine, Alessandra di Bacco, Philippe Moreau and Paul G. Richardson

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

  • Gene expression and risk of leukemic transformation in myelodysplasia
    Yusuke Shiozawa, Luca Malcovati, Anna Gallì, Andrea Pellagatti, Mohsen Karimi, Aiko Sato-Otsubo, Yusuke Sato, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hideki Makishima, Jacqueline Boultwood, Eva Hellström-Lindberg, Satoru Miyano, Mario Cazzola and Seishi Ogawa

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

  • Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2
    Hasan Hashem, Ashish R. Kumar, Ingo Müller, Florian Babor, Robbert Bredius, Jignesh Dalal, Amy P. Hsu, Steven M. Holland, Dennis D. Hickstein, Stephen Jolles, Robert Krance, Ghadir Sasa, Mervi Taskinen, Minna Koskenvuo, Janna Saarela, Joris van Montfrans, Keith Wilson, Barbara Bosch, Leen Moens, Michael Hershfield and Isabelle Meyts on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation

BLOOD WORK